Literature DB >> 15551024

Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle.

Dalila Laoudj-Chenivesse1, Gilles Carnac, Catherine Bisbal, Gerald Hugon, Sandrine Bouillot, Claude Desnuelle, Yegor Vassetzky, Anne Fernandez.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant neuromuscular disorder, has been causally related to deletion of tandemly arrayed 3.3 kb repeats (D4Z4) on chromosome 4q35. Although increased expression of several 4q35 genes has been reported, two recent studies dispute this, finding no significant changes in the transcriptional level of any of the 4q35 genes, among which is the heart and muscle-specific isoform of the adenine nucleotide translocator (ANT1). We found markedly increased levels of ANT1 protein in both unaffected and affected FSHD muscles in comparison to control healthy muscles. Comparative protein expression analysis between healthy, Duchenne muscular dystrophy, and FSHD muscle shows that proteins involved in mitochondrial function and protection from oxidative stress are also reproducibly and specifically modified in all FSHD muscles, including clinically unaffected muscles. Increased ANT1 expression and mitochondrial dysfunction may thus be initial events in FSHD pathogenesis and represent potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551024     DOI: 10.1007/s00109-004-0583-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  39 in total

1.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

2.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy.

Authors:  Petra G M van Overveld; Richard J F L Lemmers; Lodewijk A Sandkuijl; Leo Enthoven; Sara T Winokur; Floor Bakels; George W Padberg; Gert-Jan B van Ommen; Rune R Frants; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2003-11-23       Impact factor: 38.330

3.  Linkage analyses of five chromosome 4 markers localizes the facioscapulohumeral muscular dystrophy (FSHD) gene to distal 4q35.

Authors:  B Weiffenbach; R Bagley; K Falls; C Hyser; D Storvick; S J Jacobsen; P Schultz; J Mendell; K Willems van Dijk; E C Milner
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

Review 4.  Protein oxidation in aging, disease, and oxidative stress.

Authors:  B S Berlett; E R Stadtman
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

5.  A radiation hybrid map of 15 loci on the distal long arm of chromosome 4, the region containing the gene responsible for facioscapulohumeral muscular dystrophy (FSHD).

Authors:  S T Winokur; B Schutte; B Weiffenbach; S S Washington; D McElligott; A Chakravarti; J H Wasmuth; M R Altherr
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

6.  FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit.

Authors:  J C van Deutekom; C Wijmenga; E A van Tienhoven; A M Gruter; J E Hewitt; G W Padberg; G J van Ommen; M H Hofker; R R Frants
Journal:  Hum Mol Genet       Date:  1993-12       Impact factor: 6.150

7.  Human muscle proteins: analysis by two-dimensional electrophoresis.

Authors:  C S Giometti; M J Danon; N G Anderson
Journal:  Neurology       Date:  1983-09       Impact factor: 9.910

Review 8.  Muscle protein analysis by two-dimensional gel electrophoresis.

Authors:  C S Giometti
Journal:  Crit Rev Clin Lab Sci       Date:  1982       Impact factor: 6.250

9.  Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment?

Authors:  M Sandri; A H El Meslemani; C Sandri; P Schjerling; K Vissing; J L Andersen; K Rossini; U Carraro; C Angelini
Journal:  J Neuropathol Exp Neurol       Date:  2001-03       Impact factor: 3.685

10.  Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes.

Authors:  D B Zorov; C R Filburn; L O Klotz; J L Zweier; S J Sollott
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  48 in total

1.  The Krüppel-like factor 15 as a molecular link between myogenic factors and a chromosome 4q transcriptional enhancer implicated in facioscapulohumeral dystrophy.

Authors:  Petr Dmitriev; Andrei Petrov; Eugenie Ansseau; Luiza Stankevicins; Sébastien Charron; Elena Kim; Tomas Jan Bos; Thomas Robert; Ahmed Turki; Frédérique Coppée; Alexandra Belayew; Vladimir Lazar; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy patients versus normal human myoblasts.

Authors:  Andrei Petrov; Iryna Pirozhkova; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

3.  Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients.

Authors:  Petr Dmitriev; Luiza Stankevicins; Eugenie Ansseau; Andrei Petrov; Ana Barat; Philippe Dessen; Thomas Robert; Ahmed Turki; Vladimir Lazar; Emmanuel Labourer; Alexandra Belayew; Gilles Carnac; Dalila Laoudj-Chenivesse; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2013-10-20       Impact factor: 5.157

4.  An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies.

Authors:  Darko Bosnakovski; Zhaohui Xu; Eun Ji Gang; Cristi L Galindo; Mingju Liu; Tugba Simsek; Harold R Garner; Siamak Agha-Mohammadi; Alexandra Tassin; Frédérique Coppée; Alexandra Belayew; Rita R Perlingeiro; Michael Kyba
Journal:  EMBO J       Date:  2008-10-02       Impact factor: 11.598

5.  DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1.

Authors:  Manjusha Dixit; Eugénie Ansseau; Alexandra Tassin; Sara Winokur; Rongye Shi; Hong Qian; Sébastien Sauvage; Christel Mattéotti; Anne M van Acker; Oberdan Leo; Denise Figlewicz; Marietta Barro; Dalila Laoudj-Chenivesse; Alexandra Belayew; Frédérique Coppée; Yi-Wen Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

6.  Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats.

Authors:  Darko Bosnakovski; Randy S Daughters; Zhaohui Xu; Jonathan M W Slack; Michael Kyba
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

Review 7.  The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy.

Authors:  Daphne Selvaggia Cabianca; Davide Gabellini
Journal:  J Cell Biol       Date:  2010-12-13       Impact factor: 10.539

8.  DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation.

Authors:  Eugénie Ansseau; Dalila Laoudj-Chenivesse; Aline Marcowycz; Alexandra Tassin; Céline Vanderplanck; Sébastien Sauvage; Marietta Barro; Isabelle Mahieu; Axelle Leroy; India Leclercq; Véronique Mainfroid; Denise Figlewicz; Vincent Mouly; Gillian Butler-Browne; Alexandra Belayew; Frédérique Coppée
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

9.  DNaseI hypersensitivity at gene-poor, FSH dystrophy-linked 4q35.2.

Authors:  Xueqing Xu; Koji Tsumagari; Janet Sowden; Rabi Tawil; Alan P Boyle; Lingyun Song; Terrence S Furey; Gregory E Crawford; Melanie Ehrlich
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

10.  Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects.

Authors:  Marietta Barro; Gilles Carnac; Sébastien Flavier; Jacques Mercier; Yegor Vassetzky; Dalila Laoudj-Chenivesse
Journal:  J Cell Mol Med       Date:  2008-05-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.